About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Massachusetts | 445 Studies

Clinical Trials Ovarian CancerMassachusetts

Ovarian Cancer Clinical Trials in Massachusetts

Find 445 clinical trials for ovarian cancer near Massachusetts. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Massachusetts

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 21-40 of 445 trials

TerminatedPROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid TumorsThe purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in…NCT03149549·Los Angeles, California and 25 others CompletedA Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid TumorsTo determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic…NCT01248949·Los Angeles, California and 9 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerThis is a clinical study that has three parts.NCT07213804·Birmingham, Alabama and 263 others

Active not recruitingStudy of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.NCT03393884·Birmingham, Alabama and 20 others

Active not recruitingA Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian MassOvarian cancer is a serious health risk with the highest death rate among gynecological cancers.NCT06566716·Chandler, Arizona and 18 others

Terminated(VELA) Study of BLU-222 in Advanced Solid TumorsThis is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of…NCT05252416·Little Rock, Arkansas and 22 others

TerminatedATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerThe purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with elimusertib in combination with niraparib.NCT04267939·Boston, Massachusetts and 2 others

CompletedCOM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in…NCT04570839·Chicago, Illinois and 8 others

CompletedOxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based ChemotherapyRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00005836·Birmingham, Alabama and 73 others

RecruitingTegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsThis phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or…NCT04851119·Birmingham, Alabama and 20 others

CompletedGefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal CancerRATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer or primary peritoneal…NCT00023699·Birmingham, Alabama and 52 others

CompletedGenetic Testing for Breast, Ovarian, Pancreatic, and Prostate CancersThis study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.NCT04330716·Boston, Massachusetts and 5 others

TerminatedA Study of SGN-STNV in Advanced Solid TumorsThis trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.NCT04665921·Los Angeles, California and 17 others

CompletedCabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerThis randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian…NCT01716715·Mobile, Alabama and 172 others

Active not recruitingA Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsThe main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid…NCT06607185·Birmingham, Alabama and 44 others

CompletedTLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian CancerThis is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.NCT00051948·Santa Monica, California and 5 others

CompletedStudy With Afuresertib and Paclitaxel in Platinum Resistant OvarianAfuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC)…NCT04374630·Phoenix, Arizona and 46 others

TerminatedPhase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway AlterationsA Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.NCT02607813·Boston, Massachusetts and 17 others

CompletedBOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and RenewalThis research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with gynecologic and gastrointestinal cancers and their…NCT03367247·Boston, Massachusetts

Active not recruitingStudy of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsThis is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with…NCT03170960·Gilbert, Arizona and 123 others

PreviousPage 2 of 23Next

Other Conditions in Massachusetts

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia